Reviews on remdesivir in Covid-19 treatment
Remdesivir (GS-5734; Gilead Sciences Inc., US) is an investigational nucleoside analog that acts as a competitive inhibitor of viral RNAdependent
Tag: clinical trials
Gilead debates WHO results on low effectivity of remdesivir in Covid-19 mortality rate
Pharmafile reports that Gilead’s antiviral therapy remdesivir has emerged as one of the most promising drugs to treat COVID-19 infections,
Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis
The systematic review published recently in Clinical Microbiology and Infection was based on 29 articles [1]. All studies except one
Two coronavirus vaccines show immune response in human trials
Advanced Science News published on the results of clinical trials of two vaccines against SARS-CoV-2. Three months ago, the University of
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
In a pandemic like Covid-19 the urgent need excludes the development of new drugs, “conventional drug in new use” becomes
Vaccines against COVID-19
Vaccines against COVID-19 will hopefully give broad parts of the human population a safe level of immunity and are considered
Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
Amirian and Levy have recently collected the knowledge on remdesivir and its nucleoside analog [1]. This overview can be interesting
Gilead’s remdesivir significantly reduces COVID-19 symptoms in rhesus monkeys in NIH trial
A recently published study from the National Institutes of Health reports on the efficacy of Gilead’s promising antiviral therapy remdesivir
International Conference on Alzheimer’s Disease & Dementia
International Conference on Alzheimer’s Disease & Dementia is scheduled Hilton Rome Airport ,Rome, Italy from July 20 – 22, 2020. This International Conference